Diagnosis & Disease Information

Researchers proposed lowering the circulating plasma cell threshold from 20% to 5% for plasma cell l

clonoSEQ and MRD Testing in Multiple Myeloma and ALL

Medicare coverage has been announced for Adaptive Biotechnologies’ clonoSEQ® next-generation sequencing assay for the detection of minimal residual disease (MRD) after treatment for multiple myeloma or B-cell acute lymphoblastic leukemia (ALL) — a key step toward its use for patient care in cancer clinics in the United States.1,2The FDA announced regulatory approval for the assay…

Next post in Lymphoma